Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.
Griffiths, John R
Smith, Duncan L
Dempsey, Clare E
Miller, Crispin J
AffiliationChildren's Cancer Group, Institute of Cancer Science, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom
MetadataShow full item record
AbstractDespite the high cure rates in childhood acute lymphoblastic leukemia (ALL), relapsed ALL remains a significant clinical problem. Genetic heterogeneity does not adequately explain variations in response to therapy. The chemoprotective tumor microenvironment may additionally contribute to disease recurrence. This study identifies metabolic reprogramming of leukemic cells by bone marrow stromal cells (BMSC) as a putative mechanism of drug resistance. In a BMSC-extracellular matrix culture model, BMSC produced chemoprotective soluble factors and facilitated the emergence of a reversible multidrug resistant phenotype in ALL cells. BMSC environment induced a mitochondrial calcium influx leading to increased reactive oxygen species (ROS) levels in ALL cells. In response to this oxidative stress, drug resistant cells underwent a redox adaptation process, characterized by a decrease in ROS levels and mitochondrial membrane potential with an upregulation of antioxidant production and MCL-1 expression. Similar expanded subpopulations of low ROS expressing and drug resistant cells were identified in pre-treatment bone marrow samples from ALL patients with slower response to therapy. This suggests that the bone marrow microenvironment induces a redox adaptation in ALL subclones that protects against cytotoxic stress and potentially gives rise to minimal residual disease. Targeting metabolic remodeling by inhibiting antioxidant production and antiapoptosis was able to overcome drug resistance. Thus metabolic plasticity in leukemic cell response to environmental factors contributes to chemoresistance and disease recurrence. Adjunctive strategies targeting such processes have the potential to overcome therapeutic failure in ALL.
CitationStromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. 2015: Oncotarget
- Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
- Authors: Habiel DM, Krepostman N, Lilly M, Cavassani K, Coelho AL, Shibata T, Elenitoba-Johnson K, Hogaboam CM
- Issue date: 2016 Dec 13
- Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
- Authors: Zhao H, Shi P, Deng M, Jiang Z, Li Y, Kannappan V, Wang W, Li P, Xu B
- Issue date: 2016 Dec 20
- BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
- Authors: Slone WL, Moses BS, Hare I, Evans R, Piktel D, Gibson LF
- Issue date: 2016 Apr 26
- MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
- Authors: Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P
- Issue date: 2013 Mar
- Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
- Authors: Ganguly A, Basu S, Banerjee K, Chakraborty P, Sarkar A, Chatterjee M, Chaudhuri SK
- Issue date: 2011 May